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Infection by some types of human papillomavirus (HPV) has been
established to be causally related both to cervical cancer and to
cervical intraepithelial neoplasia (CIN) (IARC, 1995). Existing
evidence derives mainly from cross-sectional case-control studies
that found high frequencies of HPV infection in invasive cancers
and in CIN at the time of diagnosis and low frequencies in con-
trols with negative cytology (see references in IARC, 1995). On
this basis HPV DNA testing has been suggested as a possible
primary test, with or without conventional cytology, for the
screening of cervical cancer (Meijer et al, 1992; Solomon, 1993;
Richart, 1995; Cuzick, 2000).
The effectiveness and cost of HPV testing as a primary
screening method depends on its ability to predict a future diag-
nosis of CIN. In particular, if HPV-negative women were at very
low risk of developing high-grade CIN for many years, this would
allow screening them at longer intervals and concentrating on
HPV-positive subjects.
Some follow-up studies provide evidence that persistence of
high-risk HPV infection is needed for progression to high-grade
lesions of women with abnormal cytology (Ho et al, 1995;
Remmink et al, 1995; Nobbenhuis et al, 1999). One population
study on the risk of squamous intraepithelial lesions (SIL) (Liaw et
al, 1999) and one of invasive cancer (Wallin et al, 1999) subse-
quent to HPV detection in cytologically normal women have
recently been published. Other, previous, studies were based on
small number of cases (Walboomers et al, 1995; Rozendaal et al,
1996). Similar follow-up studies performed before 1995 are
reviewed in the IARC monograph on HPV (IARC, 1995). The
number of observed cases was always small (never reached 30)
and follow-up duration generally limited. None of them used PCR
for HPV detection: methods of more limited accuracy like dot-blot
or filter in situ hybridization were more commonly used. In some
cases selected populations (e.g. recruited in sexually transmitted
disease clinics) were studied.
We performed a case-control study by testing previous cytologic-
ally negative smears for HPV DNA, in order to estimate the value
of HPV testing in predicting histologically confirmed high-grade
CIN at different time intervals.
MATERIALS AND METHODS
The setting was the organized screening programme for cervical
cancer in Florence (Italy) that has been active for many years (Palli
et al, 1990). Cervical cytology is the primary screening method
and is recommended every third year. Women aged 25 to 64 years
who are found not to have had cervical cytology within 3 years are
invited. Women outside this age class can have spontaneous
cytology: some 7% of screened women are younger than 25 years.
The screening interval can be shorter than 3 years when a woman
performs tests upon request: the average interval between
screening exams is 2.8 years. Cytology is classified according to
the Bethesda system, using standard forms. Women are referred
for colposcopy if cytology shows low-grade squamous intraepithe-
lial lesion (LSIL) or more severe abnormalities. Cases of atypical
cells of undetermined significance (ASCUS) were routinely
referred for colposcopy until October 1996, while after that date
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ation and colposcopy are centralized. All cytological and
histological results of women screened within the organized
programme have been registered on a computerized database since
1980. Some 80% of smears performed by Florence inhabitants 
are interpreted in the centralized laboratory. Quality assurance
programmes, including circulation of standard sets of smears
(Confortini et al, 1993) and peer review of abnormal smears 
(Palli et al, 1993) are routinely implemented. Biopsies performed
outside the organized programme are routinely obtained through
the local cancer registry.
All women screened, independently of invitation, were consid-
ered. Of these, the eligible women were those who (a) had 2 or
more smears, (b) had the last cytology (index smear) performed
between January 1992 and March 1998, (c) were never referred for
colposcopy at previous cytology tests and had no history of CIN.
Cases were eligible subjects with a histologically confirmed
diagnosis of CIN II or more severe lesion after the index smear. All
smears taken within 6 years before the index smear (and in any
case after 1989), but not the index smear itself, were retrieved 
and independently reviewed by 3 of the authors (MC, FC, CM).
Smears classified as SIL or more severe at review were excluded.
Potential controls were women not referred for colposcopy at the
last (index) smear. One previous smear was retrieved for each
control. We sampled the eligible population for 3 control smears
per case smear, matched to cases by age (±3 years), by year of the
index smear, and by interval from the index smear (±1 year).
DNA from a pool of major interest high-risk HPV types (16, 18,
31, 33, 52, 58) was searched for on retrieved smears.
Molecular analysis
In order to remove cells from archived slides, Pap smears were
soaked in xylene for 2 to 6 days until the coverslips were removed,
then destained in a solution of ethanol 70% and HCl 0.1% for 5–10
minutes. Cells were scraped from the slide with a clean new slide
and transferred into an Eppendorf tube. To maximize the yield,
DNA isolation was performed using a method based on a high
capacity silica matrix (Roda Husman de et al, 1995) in the pre-
sence of the chaotropic agent guanidium thiociate (Quiagen tissue
kit).
To analyse the quality of the target DNA, the samples were
screened by PCR using β -globin specific primers (PC04-GH20)
spanning 268 base pairs (bp). Only samples that tested positive for
β -globin were further analysed.
Testing for human papillomavirus was done by PCR, using
consensus pU-1M and pU-2R primers (Fujinaga et al, 1991)
within the E6-E7 region of high-risk HPV types 16, 18, 31, 33, 52
and 58. This test provides a simple accurate mean of detecting a
broad range of high-risk HPVs and has been clinically validated
(Fujinaga et al, 1991). The pU-1M/pU-2R primers pair yielded a
PCR product of 233 to 268bp when DNA of HPV types 16, 18,
31, 33, 52 or 58 is present in the sample.
The sample (5 µ l) was added to 40 µ l of PCR mixture (BIOLINE
Diagnostici s.r.l., Turin, Italy) containing dNTP, MgCl2 and primers
in PCR buffer. During the first denaturation step, 5 µ l of Taq
Polymerase (2.5 units) were added (hot start technique). The PCR
reaction was performed in a total volume of 50 µ l. The termal
cycling conditions were 94˚C for 5min, then 40 cycles at 94˚C for
1min, 55˚C for 1min, 72˚C for 1min and finally 72˚C for 5min,
using Omnigene Thermal Cycler (Hybaid Ltd).
In each run of amplification analysis a negative control and a
positive control were included, to verify the results and to avoid
false positive signals due to contamination. PCR positive control
consisted of extracted DNA from the CaSki cell line which
contains HPV 16 (Kreatech Diagnostics). Sterile water was used
as the negative control. Regarding sample, the analyst was not
aware of case/control status.
The amplified products were applied to 2% agarose gel
containing ethidium bromide and electrophoresed. The DNA were
visualized under ultraviolet (UV) transillumination. A band of
233–268bp size indicated a positive samples for a HPV from the
high risk pool (16, 18, 31, 33, 52, 58) (Figure 1).
Statistical methods
Only smears in which β -globin DNA was identifiable were used
for the analysis. Smears were the statistical units in every analysis.
If a case had smears taken at different intervals before the index
smear, each of them provided information on the subject’s HPV
status at the corresponding interval. As observations from the
same subject are possibly correlated, test results cannot be
assumed to be independent. Therefore test statistics and confi-
dence intervals are not correct with standard procedures. We took
this into account by use of Generalized Estimating Equations
(GEE) (Zeger and Liang, 1986).
As multiple case and control smears had the same matching
covariable values, we computed the OR between case/control
status and the result of HPV testing, adjusting (Mantel-Heanszel
OR) with strata that grouped case and control smears with the
same combination of covariables (including exact age)
(Brookmeyer et al, 1986). The same OR was also computed by
unconditional logistic regression, adjusting for age class and for
interval from the index smear and applying GEE in order to have
correct confidence intervals.
We studied a possible modification of HPV effect by test-
index smear interval by adding a HPV × interval interaction 
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Figure 1 E6–E7 amplification products. DNA was electrophoresed on 2%
agarose gel, stained by ethidium bromide, visualized and photographed
under UV light. Lane MW: molecular weight, 100bp DNA ladder (Genenco,
Florence, Italy). Lane C+: positive control, DNA from CaSki cells. Lane 
C–: negative control, sterile water. Lanes 1 to 7: DNA from clinical
specimens. Samples 2 and 6 were positive for high-risk HPV DNA; samples
1, 3, 4, 5, 7 were negative.term. Interval was re-grouped in two classes (> 4 years and ≥ 4
years).
We studied the variations in the proportion of HPV-positive
smears, by age and by interval between tested and index smears,
within cases and controls, using unconditional logistic regression.
For cases we applied GEE. GEE were also used in order to obtain
correct confidence intervals for the proportion of HPV positive
smears at intervals < 4 years and ≥ 4 years (Ronco and Biggeri,
1999).
RESULTS
We retrieved 104 smears from cases and 350 from controls.
Among case smears 5 were excluded because they were classified
as SIL at review and 7 because β -globin DNA could not be identi-
fied. 18 control smears were also excluded for the latter reason.
We identified β -globin DNA in 92 smears from 79 cases (15 CIN
II, 59 CIN III, 5 invasive cancers) and in 332 smears from
controls. A single study smear was available for 69 cases, 2 for 8
cases, 3 for one case and 4 for another. About half the case and
control smears were taken at age ≥ 35 years (Table 1). Only 2 case
and 7 control smears were taken before age 25. The mean interval
between test and index smear was 2.5 years (Table 2).
Among case smears 71 (77.17%) were positive for high-risk
HPV DNA, vs. 17 (5.12%) control smears, with an OR (adjusted
for age class and interval between the test smear and the 
index smear) of 63.76 (95% CI 30.57–132.96). The corresponding
Mantel-Haenszel OR, with strata grouping case and control 
smears with the same combination of matching covariables
(including exact age) was 61.72. The OR was significantly higher
(z robust = –2.26, P = 0.024) for smears taken less than 4 years
before the index one (OR = 102.94, 95% CI 42.63–250.72) than
for those taken at longer interval (OR = 21.00, 95% CI
7.22–61.21).
Among cases, the proportion of HPV-positive smears showed
little variation by age. Among controls there was a statistically not
significant reduction from 5.6% in smears taken until 44 years of
age to 2.3% in smears taken at older ages (Table 1).
Among cases, most smears remained HPV positive even 5–6
years before the index smear (Table 2). A slight decrease with an
increasing test-index smear interval was not statistically signifi-
cant (z robust for linear trend = –0.75, P = 0.453). High-risk HPV
DNA was found in 81.24% (95% CI 69.93–88.96%) and 67.80%
(95% CI 47.72–82.93%) of case smears, for intervals from the
index smear of < 4 years and ≥ 4 years respectively.
In order to study the duration of HPV infection before a high-
grade lesion arises, we also considered the midpoint between the
index smear and the last previous negative cytology and we
studied HPV presence as a function of time before it (Table 3). The
picture changed only very slightly.
Previous smears from cases were reviewed before HPV testing.
Some 30 smears were re-classified as ASCUS. When excluding
them, the proportion of smears containing high-risk HPV DNA
was 79.11% (95% CI 64.35–88.82%) and 57.96% (95% CI
36.83–76.53%) for intervals from index smear < 4 and ≥ 4 years,
respectively. The duration of HPV infection before the start of
CINII+ was also re-computed excluding smears classified as
ASCUS at review if no further smear ‘within normal limits’ was
present. Results (Table 3) were only slightly different from those
based on all cases.
Among controls the proportion of HPV-positive smears was
substantially constant across test-index smear intervals (Table 2)
(χ 2 for linear trend = –1.07, P = 0.301).
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Table 1 Distribution of case and control smears by age at smear-taking and
presence of high-risk HPV
Case smears Control smears
Number of No. (%) positive Number of No. (%) positive
smears for high-risk smears for high-risk
HPV HPV
< 35 49 37 (75.5) 178 10 (5.6)
35–44 32 26 (81.3) 110 6 (5.5)
45–54 8 6 (75.0) 28 1 (3.6)
55+ 3 2 (66.7) 16 0
Total 92 71 (77.1) 332 17 (5.1)
Age at 
smear 
taking 
(years)
Table 2 Distribution of case and control smears by interval from the index
smeara and presence of high-risk HPV
Case smears Control smears
Number  No. (%) positive Number No. (%) positive
of smears for high-risk of smears for high-risk
HPV HPV
<1 7 6 (85.7) 6 0
1 16 12 (75.0) 104 6 (5.8)
2 17 13 (76.5) 68 2 (2.9)
3 24 21 (87.5) 76 2 (2.6)
4 18 12 (66.7) 45 4 (8.9)
5 7 5 (71.4) 24 1 (4.2)
6 3 2 (66.7) 9 2 (22.2)
Total 92 71 (77.1) 332 17 (5.1)
a‘Index smear’ is the last cytology before diagnosis of CIN for cases and the
last available negative smear for controls.
Interval
between
test and
index smear
(years)
Table 3 Distribution of case smears by interval before the start of CIN2+ and presence of high-risk HPV
All smears Excluding smears classified as ASCUS at reviewb
No. of smears No. (%) HPV positive No. of smears No. (%) HPV positive
< 1 22 17 (77.3) 72.26% 15 11 (73.3) 74.58%
1–2 41 34 (82.9) (95% CI 28 23 (82.1) (95% CI
2–3 19 14 (73.7) 69.92–86.60%) 13 7 (53.9) 62.32–83.97%)
3–4 7 4 (57.1) 60.60% 3 2 (66.7) 71.43%
4–5 2 1 (50.0) (95% CI 2 1 (50.0) (95% CI
5–6 1 1 (100) 26.44–85.86%) 1 1 (100) 29.14–94.35%)
aThe midpoint between the last negative cytology and the index smear was used as a proxy for CIN2+ start. bSmears classified as ASCUS at review were
excluded if no further smear ‘within normal limits’ was available.
Interval before start of
CIN2+a (years)
}
}
}
}HPV before CIN 1465
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DISCUSSION
Our results are based on a population putatively representative of
cervical screening target groups in industrialized countries. They
show that infection from high-risk HPV types is present some
years before diagnosis in a high proportion of women who will
develop high-grade CIN. According to our data, HPV DNA testing
predicts the development of a high-grade lesion 3 years before the
conventional diagnosis in some 80% of cases and 6 years before it
in 2/3 of cases.
We observed only a slight decrease, if any, in the proportion of
HPV-positive smears with an increasing time interval before diag-
nosis, suggesting that in most cases high-risk HPV infection has a
long duration before a high-grade lesion arises.
Decrease remains slight when considering the midpoint
between the last negative smear and the index smear as a proxy of
the starting date of high-grade lesion. We did not consider that
CIN II–III could actually have already been present despite
negative cytology confirmed at review. It is not plausible for this
to have substantially biased our estimates.
Some 20% of high-grade lesions appear not to be preceded by
HPV infection. This figure is similar to the proportion of HPV
negative high-grade lesions found in less recent cross-sectional
studies (IARC, 1995) although recent studies found a higher sensi-
tivity (Kjellberg et al, 1998; Clavel et al, 1999; Schiffman et al,
2000). Our results, based on archival smears, could underestimate
the diagnostic prediction that could be obtained by HPV testing
with fresh material.
Controls represent a sample of subjects that remained cytologic-
ally negative at least for a time equal to the interval between the
test and the index smear. Our data show good specificity of HPV
testing since only a small minority of control smears contained
high-risk HPV DNA. Such a proportion seems to be fairly stable
for the studied test-index smear intervals.
Controls were matched to cases by age, over-representing
young ages when compared to the screened population. This could
result in an underestimate of overall specificity. Age variation
within our controls, although not statistically significant, is in
agreement with existing data (Melkert et al, 1993; Burk et al,
1996; Svare et al, 1998). In addition, women with more smears
had a higher probability of being selected as controls. A higher
frequency of tests could depend on vaginal symptoms, reflecting
different sexual behaviour and therefore different probability of
HPV infection.
We did not analyse smears for low-risk HPV types. It is possible
that some cases that we found negative would test positive for
these types. On the other hand this plausibly would also increase
the proportion of positive controls, reducing specificity. High
specificity is crucial for mass screening.
In our study no obvious selection or information (molecular
analysts were blind to case/control status) bias leading to overestim-
ation of the HPV-CIN association is present. Random misclassifi-
cation of HPV status, if present, is expected to lead to a dilution
of such association. We considered multiple smears for some
subjects. This could have caused bias in estimates if the number of
tests was associated with HPV result (Zeger and Liang, 1986).
This is not the case in our study: among the 69 smears from cases
with a single test 78.3% were HPV positive against 73.9% of the
23 smears from cases with multiple tests (P = 0.7). This, however
very small difference was even smaller when adjusting for interval
from the index smear.
We studied CINII+ cases arisen in women never referred for
colposcopy at previous screening rounds. Women with previous
colposcopy history were not suitable for studying the natural
history of disease because diagnostic and follow-up procedures
could have changed it. In Florence, women with at least low-grade
cytology (and until recently with ASCUS) had been referred for
colposcopy. This does not mean that study cases did not progress
from low-grade lesions: low-grade lesions could have started and
progressed to HSIL between screening tests. However, plausibly,
the period during which LSIL/ASCUS cytology remained
detectable was, on average, shorter in study cases. It is possible
that the overall duration of HPV infection before CINII+ develop-
ment was different in cases previously referred for colposcopy.
A few previous studies considered the risk of cervical invasive
or intraepithelial neoplasm subsequent to HPV detection in cyto-
logically normal women. An association between HPV infection
and subsequent development of invasive cancer was found by a
recent case-control study (Wallin et al, 1999). This study, however,
finds a lower proportion of HPV-positive smears before diagnosis
(18/48 and 13/35 at time lags <3 years and 3–6 years before cancer
diagnosis, respectively) than we do. Studied cancers arose in a
screened population: failure to prevent them could have resulted
from a more rapid progression than that of prevented cancers. The
average duration of pre-invasive lesions before invasive cancer
has been estimated to be more than 10 years (Gustafsson and
Adami, 1989; Oortmarssen van et al, 1991). In a similar study
(Walboomers et al, 1995), among 26 negative archival smears,
taken in 18 women developing cervical cancer up to 6 years later,
24 showed HPV infection (23 from high-risk types).
Out of 7 CIN III cases diagnosed in 1622 women in an average
follow-up of 40 months after normal cytology, 6 were initially
positive to a PCR-based high-risk HPV test (Rozendaal et al,
1996). The 5-year follow-up of a large cohort (Liaw et al, 1999)
also found a strong association between HPV infection in cytologic-
ally normal women and subsequent SIL. It found a strong increase
in risk of SIL (mainly low-grade or ASCUS) in the first few years
after HPV infection. Results on high-grade lesions suggested
slightly shorter infection duration before high-grade lesions than
our data do.
Indirect support to our estimates comes from data on prevalence
of HPV infection and of high-grade intraepithelial lesions by age
(Schiffman, 1992). The former peak at the beginning of sexual
activity (Morrison et al, 1991; Melkert et al, 1993, Burk et al,
1996) and the latter 5–10 ages later, in the early thirties (review in
Gustaffson and Adami, 1992).
It has been shown that HPV testing, combined with cytology,
can improve sensitivity in detecting the presence of histologically
confirmed high-grade lesions (Cuzick et al, 1995, 1999). Recently
HPV testing by Hybrid Capture II has been shown to be able to
provide better sensitivity (88.4%) than conventional cytology
(77.7%) for high-grade lesions, with a specificity (89.0%) accept-
able but lower than that of cytology (94.2%) (Schiffman et al,
2000).
Our results suggest that HPV testing could be applied to
screening for cervical cancer, by selecting a sub-population with a
very low probability of developing a pre-invasive lesion for many
years and another with a relatively high probability. The former
could safely be invited for a new test at long intervals while the
latter could be followed up at short intervals. The detection rate of
histologically confirmed high-grade CIN in the Florence screening
is 2.2 per thousand. Applying our data to such a situation, 350 per10 000 women with high-risk HPV DNA will have a CIN II+ diag-
nosis at the next 3-year screening round compared to 4.5 per 10
000 in HPV-negative women. The mentioned detection rate
includes cases arisen in women with a colposcopy history at
previous rounds while our ‘sensitivity’ estimates do not (see
above). Therefore a slight over- or underestimate is possible.
In a simulation study (Ballegoijen van et al, 1997), when a 10-
year duration of infection before progression to CIN was assumed,
10-yearly HPV testing provided greater protection than 3-yearly
conventional cytology. Outcomes were the opposite when
assuming a 1-year duration. At that time the authors could not
reach a conclusion because available studies did not allow reliable
assumptions for this parameter. Our results suggest long duration
and, therefore, good cost-effectiveness in screening for cervical
cancer based on long-interval HPV testing. Caution is however
needed.
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